TAP-inhibitors from old world primate 1-herpesviruses and their use: WO2009008713

Expert Opinion on Therapeutic Patents

Volumn 20, Issue 2, 2010, Pages 277-282

  Raghavan, Malini ^a  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

Cytotoxic T lymphocyte; Herpesviruses; MHC class I; Transporter associated with antigen processing

Indexed keywords

EPITOPE; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; PROTEIN INHIBITOR; TRANSPORTER ASSOCIATED WITH ANTIGEN PROCESSING 1; TRANSPORTER ASSOCIATED WITH ANTIGEN PROCESSING 1 INHIBITOR; UNCLASSIFIED DRUG; WO 2009008713;

AUTOIMMUNITY; CANCER IMMUNOTHERAPY; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; DRUG MECHANISM; DRUG SYNTHESIS; EPSTEIN BARR VIRUS; HERPES SIMPLEX VIRUS 1; IMMUNE RESPONSE; NUCLEOTIDE SEQUENCE; PROTEIN ANALYSIS; PROTEIN EXPRESSION; REVIEW;

ANIMALS; ANTIGEN PRESENTATION; ATP-BINDING CASSETTE TRANSPORTERS; EPITOPES, T-LYMPHOCYTE; HERPESVIRIDAE; HERPESVIRUS 4, HUMAN; HISTOCOMPATIBILITY ANTIGENS CLASS I; IMMUNOTHERAPY; LYMPHOCRYPTOVIRUS; NEOPLASMS; PATENTS AS TOPIC; PEPTIDES; PROTEIN TRANSPORT; T-LYMPHOCYTES, CYTOTOXIC; VIRUS DISEASES;

EID: 76149093857     PISSN: 13543776     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543770903501563     Document Type: Review

References (34)

1. Bjorkman PJ, Saper MA, Samraoui B, et al.. Structure of the human class I histocompatibility antigen, HLA-A2. Nature 1987;329(6139):506-512
2. Hansen TH, Bouvier M. MHC class I antigen presentation: learning from viral evasion strategies. Nat Rev Immunol 2009;9(7):503-513
3. Procko E, Gaudet R. Antigen processing and presentation: TAPping into ABC transporters. Curr Opin Immunol 2009;21(1):84-91
4. Raghavan M, Del Cid N, Rizvi SM, et al.. MHC class I assembly: out and about. Trends Immunol 2008;29(9):436-443
5. Scholz C, Tampe R. The intracellular antigen transport machinery TAP in adaptive immunity and virus escape mechanisms. J Bioenerg Biomembr 2005;37(6):509-515
6. Peaper DR, Cresswell P. Regulation of MHC class I assembly and Peptide binding. Annu Rev Cell Dev Biol 2008;24:343-368
7. Ahn K, Meyer TH, Uebel S, et al.. Molecular mechanism and species specificity of TAP inhibition by herpes simplex virus ICP47. Embo J 1996;15(13):3247-3255
8. Fruh K, Ahn K, Djaballah H, et al.. A viral inhibitor of peptide transporters for antigen presentation. Nature 1995;375(6530):415-418
9. Hill A, Jugovic P, York I, et al.. Herpes simplex virus turns off the TAP to evade host immunity. Nature 1995;375(6530):411-415
10. Tomazin R, Hill AB, Jugovic P, et al.. Stable binding of the herpes simplex virus ICP47 protein to the peptide binding site of TAP. Embo J 1996;15(13):3256-3266
11. Ahn K, Gruhler A, Galocha B, et al.. The ER-luminal domain of the HCMV glycoprotein US6 inhibits peptide translocation by TAP. Immunity 1997;6(5):613-621
12. Lehner PJ, Karttunen JT, Wilkinson GW, et al.. The human cytomegalovirus US6 glycoprotein inhibits transporter associated with antigen processing-dependent peptide translocation. Proc Natl Acad Sci USA 1997;94(13):6904-6909
13. Kyritsis C, Gorbulev S, Hutschenreiter S, et al.. Molecular mechanism and structural aspects of transporter associated with antigen processing inhibition by the cytomegalovirus protein US6. J Biol Chem 2001;276(51):48031-48039
14. Hewitt EW, Gupta SS, Lehner PJ. The human cytomegalovirus gene product US6 inhibits ATP binding by TAP. Embo J 2001;20(3):387-396
15. Koppers-Lalic D, Reits EA, Ressing ME, et al.. Varicelloviruses avoid T cell recognition by UL49.5-mediated inactivation of the transporter associated with antigen processing. Proc Natl Acad Sci USA 2005;102(14):5144-5149
16. Verweij MC, Koppers-Lalic D, Loch S, et al.. The varicellovirus UL49.5 protein blocks the transporter associated with antigen processing (TAP) by inhibiting essential conformational transitions in the 6+6 transmembrane TAP core complex. J Immunol 2008;181(7):4894-4907
17. Koppers-Lalic D, Verweij MC, Lipinska AD, et al.. Varicellovirus UL 49.5 proteins differentially affect the function of the transporter associated with antigen processing, TAP. PLoS Pathog 2008;4(5):e1000080
18. Ressing ME, Keating SE, Van Leeuwen D, et al.. Impaired transporter associated with antigen processing-dependent peptide transport during productive EBV infection. J Immunol 2005;174(11):6829-6838
19. Hislop AD, Ressing ME, van Leeuwen D, et al.. A CD8+ T cell immune evasion protein specific to Epstein-Barr virus and its close relatives in Old World primates. J Exp Med 2007;204(8):1863-1873
20. Croft NP, Shannon-Lowe C, Bell AI, et al.. Stage-specific inhibition of MHC class I presentation by the Epstein-Barr virus BNLF2a protein during virus lytic cycle. PLoS Pathog 2009;5(6):e1000490
21. Horst D, Van Leeuwen D, Croft NP, et al.. Specific targeting of the EBV lytic phase protein BNLF2a to the transporter associated with antigen processing results in impairment of HLA class I-restricted antigen presentation. J Immunol 2009;182(4):2313-2324
22. Wolpert EZ, Petersson M, Chambers BJ, et al.. Generation of CD8+ T cells specific for transporter associated with antigen processing deficient cells. Proc Natl Acad Sci USA 1997;94(21):11496-11501
23. Van Hall T, Wolpert EZ, Van Veelen P, et al.. Selective cytotoxic T-lymphocyte targeting of tumor immune escape variants. Nat Med 2006;12(4):417-424
24. Chambers B, Grufman P, Fredriksson V, et al.. Induction of protective CTL immunity against peptide transporter TAP-deficient tumors through dendritic cell vaccination. Cancer Res 2007;67(18):8450-8455
25. Dean M, Annilo T. Evolution of the ATP-binding cassette (ABC) transporter superfamily in vertebrates. Annu Rev Genomics Hum Genet 2005;6:123-142
26. Jugovic P, Hill AM, Tomazin R, et al.. Inhibition of major histocompatibility complex class I antigen presentation in pig and primate cells by herpes simplex virus type 1 and 2 ICP47. J Virol 1998;72(6):5076-5084
27. Van Hall T, Laban S, Koppers-Lalic D, et al.. The varicellovirus-encoded TAP inhibitor UL49.5 regulates the presentation of CTL epitopes by Qa-1b1. J Immunol 2007;178(2):657-662
28. Banchereau J, Palucka AK. Dendritic cells as therapeutic vaccines against cancer. Nat Rev Immunol 2005;5(4):296-306 (Pubitemid 40516155)
29. Tacken PJ, De Vries IJ, Torensma R, et al.. Dendritic-cell immunotherapy: from ex vivo loading to in vivo targeting. Nat Rev Immunol 2007;7(10):790-802
30. Khazaie K, Bonertz A, Beckhove P. Current developments with peptide-based human tumor vaccines. Curr Opin Oncol 2009;21(6):524-530
31. Ferris RL, Whiteside TL, Ferrone S. Immune escape associated with functional defects in antigen-processing machinery in head and neck cancer. Clin Cancer Res 2006;12(13):3890-3895
32. Kessler JH, Melief CJ. Identification of T-cell epitopes for cancer immunotherapy. Leukemia 2007;21(9):1859-1874
33. Khong HT, Restifo NP. Natural selection of tumor variants in the generation of "tumor escape" phenotypes. Nat Immunol 2002;3(11):999-1005
34. Finke LH, Wentworth K, Blumenstein B, et al.. Lessons from randomized phase III studies with active cancer immunotherapies - outcomes from the 2006 meeting of the Cancer Vaccine Consortium (CVC). Vaccine 2007;25(Suppl 2):B97-109